World’s first mRNA lung cancer vaccine enters human trials in seven countries
A landmark mRNA lung cancer vaccine is now being tested in human patients for the first time, marking a historic milestone in cancer treatment. BNT116, developed by BioNTech, uses the same messenger RNA technology behind COVID-19 vaccines to train the immune system to recognize and destroy non-small cell lung cancer cells. The phase 1 trial spans 34 sites across seven countries, with roughly 130 patients enrolled. Unlike chemotherapy, this approach targets only tumor cells, potentially offering a more precise and lasting defense against the world’s deadliest cancer, which kills 1.8 million people annually.









